» Articles » PMID: 21422797

Capturing Side-effect of Medication to Identify Persons at Risk of Delirium

Overview
Publisher Springer
Specialty Geriatrics
Date 2011 Mar 23
PMID 21422797
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Delirium, an acute confusional state characterized by decline in attention and cognition, is a common, life-threatening, but potentially preventable clinical syndrome among older persons. Deficits in cholinergic function have been postulated to cause delirium and cognitive decline. In particular, an imbalance between levels of acetylcholine and monoamine (such as dopamine) may cause delirium. We describe two cases of delirium in hospitalized older patients, supporting the "cholinergic deficiency hypothesis". In the first patient, hypo-reactive delirium developed a few hours after a dose of the long-acting opiate tramadol (a drug with anticholinergic effect) as analgesic for pain related to advanced peripheral artery disease. In the second patient, with vascular parkinsonism plus pre-frontal cortex vascular lesions, hyper-reactive delirium developed a few hours after a prescribed administration of L-dopa. These symptoms disappeared completely on the following day. These two "natural" experiments support the hypothesis that both hypo-reactive and hyper-active delirium may be caused by a reduction in cholinergic signaling.

Citing Articles

Risk Factors for Postoperative Delirium Severity After Deep Brain Stimulation Surgery in Parkinson's Disease.

Astalosch M, Mousavi M, Ribeiro L, Schneider G, Stuke H, Haufe S J Parkinsons Dis. 2024; 14(6):1175-1192.

PMID: 39058451 PMC: 11380232. DOI: 10.3233/JPD-230276.


Cerebrospinal fluid catecholamines in delirium and dementia.

Henjum K, Godang K, Quist-Paulsen E, Idland A, Neerland B, Sandvig H Brain Commun. 2021; 3(3):fcab121.

PMID: 34423298 PMC: 8374970. DOI: 10.1093/braincomms/fcab121.


Factors for Timely Identification of Possible Occurrence of Delirium in Palliative Care: A Prospective Observational Study.

Corli O, Santucci C, Uggeri S, Bosetti C, Cattaneo M, Ermolli D Adv Ther. 2021; 38(8):4289-4303.

PMID: 34228345 PMC: 8342371. DOI: 10.1007/s12325-021-01814-7.


Delirium after Deep Brain Stimulation in Parkinson's Disease.

Li H, Han S, Feng J Parkinsons Dis. 2021; 2021:8885386.

PMID: 33604017 PMC: 7872740. DOI: 10.1155/2021/8885386.


Treatment of Delirium in Older Persons: What We Should Not Do!.

Lauretani F, Bellelli G, Pela G, Morganti S, Tagliaferri S, Maggio M Int J Mol Sci. 2020; 21(7).

PMID: 32244301 PMC: 7177924. DOI: 10.3390/ijms21072397.


References
1.
Cancelli I, Valentinis L, Merlino G, Valente M, Gigli G . Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin Pharmacol Ther. 2007; 84(1):63-8. DOI: 10.1038/sj.clpt.6100435. View

2.
Lauretani F, Maggio M, Nardelli A, Saccavini M, Ceda G . Should 3,4-dihydroxy-L-phenylalanine be used routinely in vascular Parkinson?. J Am Geriatr Soc. 2008; 56(10):1977-8. DOI: 10.1111/j.1532-5415.2008.01909.x. View

3.
Cancelli I, Beltrame M, Gigli G, Valente M . Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci. 2009; 30(2):87-92. DOI: 10.1007/s10072-009-0033-y. View

4.
Young J, Inouye S . Delirium in older people. BMJ. 2007; 334(7598):842-6. PMC: 1853193. DOI: 10.1136/bmj.39169.706574.AD. View

5.
Hshieh T, Fong T, Marcantonio E, Inouye S . Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci. 2008; 63(7):764-72. PMC: 2917793. DOI: 10.1093/gerona/63.7.764. View